#Huawei joins the #Avanci #5G program On August 16, patent platform Avanci announced the launch of its 5G Connected Vehicle Program. Huawei is included in the list of licensors for the program. Avanci Said Huawei has joined its 5G and 4G programs. So far, the 5G program has 58 licensors, including the top 10 global 5G standard essential patent holders like Qualcomm, Samsung and Nokia. Mercedes-Benz is the first licensee of the program. Avanci also released its 5G program charges of $32 per vehicle, with an early-bird price to those licensed within six months. Automakers that sign licenses before the later of February 16, 2024 or first sale of 5G-connected car can enjoy a preferential rate of $29 per vehicle, subject to other terms of the license agreement. Photo: Licensors on the Avanci 5G Vehicle platform(source: Avanci) For more: https://lnkd.in/gambaU5H
China IP’s Post
More Relevant Posts
-
Dialogue with @Regina Quek, First Deputy Secretary General of @AIPPI: Connecting Global IP at the Hangzhou Congress From October 19 to 22 this year, the AIPPI World Congress will be hosted in China for the first time, marking a notable acknowledgment of China's efforts in bolstering IP protection, refining its legal framework, and improving management systems. Ahead of the event, we had the privilege of speaking with Ms. Regina Quek, the first deputy secretary-general of AIPPI. She shared exclusive insights into the highlights of the upcoming AIPPI Hangzhou Conference, AIPPI’s pivotal role in promoting international IP cooperation, and how this event is poised to further drive the growth of IP both in China and globally. Click to read the full article: https://lnkd.in/gCduvPea
To view or add a comment, sign in
-
China IP Weekly——the latest updates of global IP news #ChinaIP Focus 1. China promotes protection of geographical indications 中国推动地理标志保护 2. #Samsung hit with $192 million US patent verdict over wireless chargers 三星侵犯无线充电器专利,在美被判赔1.92亿美元 3. #IBM wins $45 million verdict against #Zynga in internet tech patent trial IBM在互联网技术专利诉讼中胜诉,获赔4500万美元 IP Practice 4. #Philips wins #UPC injunction against #Belkin 飞利浦胜诉!UPC下达了对贝尔金的禁令 5. #Nvidia sued for infringing AI computing technology 英伟达因侵犯人工智能计算技术而被起诉 6. #Ford barred from using #InterMotive mark after $13 million verdict 福特被判赔1300万美元、并被禁止使用InterMotive商标 7. #Nintendo, #Pokemon sue "Palworld" maker for patent infringement 任天堂与宝可梦公司起诉《幻兽帕鲁》制造商专利侵权 8. #Lacoste loses trademark dispute with #Crocodile Lacoste在与Crocodile的商标纠纷中败诉 Click to read the full article: https://lnkd.in/gAGtYNeW
To view or add a comment, sign in
-
China promotes protection of geographical indications China has made significant strides in promoting the protection of geographical indications (GI) in recent years, with 2,523 GI products approved and 7,385 GI trademarks registered as of the end of August, the China National Intellectual Property Administration (CNIPA) said last Saturday. Since 2020, the direct annual output value of China's GIs has shown consistent growth. In 2023, this value surpassed 961 billion yuan, as revealed at the 13th China Intellectual Property Annual Conference. Hu Wenhui, deputy commissioner of the CNIPA, highlighted that the quality and quantity of China's GI products and trademarks rank among the highest globally. He also emphasized the importance of international cooperation, expressing China's eagerness to work with the global community to bring greater benefits to people and support high-quality economic development. For more: https://lnkd.in/geYtuJNU
To view or add a comment, sign in
-
SPC upholds Schneider China's 106 million RMB victory in trademark infringement case The Supreme People's Court (SPC) recently upheld a ruling in favor of #Schneider Electric (China) Co., Ltd. (Schneider China) in a significant trademark infringement and unfair competition case against Zhenjiang Schneider Electric Co., Ltd. (Zhenjiang Schneider) and others, as announced on September 15. The SPC dismissed Zhenjiang Schneider and others' appeal and maintained the original judgment from the Zhejiang Higher People's Court. Schneider China accused Zhenjiang Schneider and others of maliciously registering a similar company name and using it to gain an unfair advantage, constituting trademark infringement and unfair competition. The Zhejiang Higher People's Court initially ruled in Schneider China's favor, ordering Zhenjiang Schneider to stop infringing on Schneider China's trademarks "Schneider" and "Schneider Electric", cease using its company name, and discontinue the domain "zj-schneider.com". Zhenjiang Schneider and others were ordered to compensate Schneider China with RMB 106,180,819 for economic losses and RMB 500,000 for legal expenses. The defendants argued Schneider China exceeded the statute of limitations, but the court found the infringement ongoing since Zhenjiang Schneider had used the infringing name since 1999. The court also determined Zhenjiang Schneider's actions caused public confusion and constituted trademark infringement and unfair competition. Additionally, the court highlighted Zhenjiang Schneider's clear malicious intent of leveraging Schneider China's brand reputation. Punitive damages were therefore applied. The amount was calculated based on Zhenjiang Schneider's profits from June 2017 to March 2022. Given the severity and duration of the infringement, the court applied a multiplier of three to the base profit amount, resulting in total damages of RMB 106,180,819. Despite Zhenjiang Schneider's appeal, the SPC found no merit in their arguments and upheld the initial ruling, affirming both the decision and the awarded damages. This case marks another significant win for Schneider China in defending its legitimate trademark rights. Earlier this year, Schneider China was awarded 40 million RMB in a similar case against a Jiangsu-based elevator manufacturer, Schneider Elevator. Photo: Oil & Gas For more: https://lnkd.in/e87Mi_c
To view or add a comment, sign in
-
China IP Weekly——the latest updates of global IP news #ChinaIP Focus 1. JUVE Patent: #UPC's initial rulings tend to restrict patents JUVE Patent:UPC的初步判决倾向于限制专利 2. China signs IP cooperation pacts with 57 BRI partner countries 我国与57个“一带一路”合作国家签署知识产权合作协议 3. #ATL sues #CosMX for infringement of five patents in the US 宁德新能源在美诉珠海冠宇五项专利侵权 IP Practice 4. #AbbVie sues rival #BeiGene over alleged theft of cancer therapy secrets 艾伯维指控百济神州涉嫌侵犯癌症疗法商业机密 5. #vivo joins Via LA's AAC patent pool vivo加入Via LA的AAC专利池 6. LG Electronics, KT Corporation and Vodafone join Sisvel Cellular IoT patent pool LG电子、KT公司和沃达丰加入Sisvel蜂窝物联网专利池 7. #Google loses fight against $2.7 billion EU antitrust fine 谷歌败诉,需支付27亿美元欧盟反垄断罚款 8. Google sued for trademark infringement over Gemini AI system 谷歌因Gemini人工智能系统商标侵权被起诉 Click to read the full article: https://lnkd.in/gpXjHmp5
To view or add a comment, sign in
-
China signs IP cooperation pacts with 57 BRI partner countries China has signed intellectual property (IP) cooperation agreements with 57 Belt and Road Initiative (BRI) partner countries, further strengthening bilateral cooperation, according to the China National Intellectual Property Administration (CNIPA). At a monthly press conference held last Wednesday, CNIPA revealed that from 2013 to 2023, BRI partner countries filed a total of 285,000 patent applications in China, with an average annual growth rate of 5.6 percent. During the same period, Chinese companies filed 70,000 patent applications and received 35,000 patent grants in BRI partner countries and related organizations, maintaining an average annual growth rate of over 20 percent. The growth momentum for digital patents within Belt and Road cooperation remains robust. From 2013 to 2023, Chinese applicants secured 27,000 invention patents in core digital economy industries from BRI partner countries and related organizations, achieving an average annual growth rate of 16.9 percent. For more: https://lnkd.in/g4aHrAaX
To view or add a comment, sign in
-
#Mindray loses in decade-long patent dispute against its rival #Comen After a decade of fierce legal battles, Mindray has suffered a significant defeat against its emerging rival, Comen. In late August, the China National Intellectual Property Administration (CNIPA) declared Mindray’s utility model patent for the "Flow Sensor and Flow Sensor Assembly" (ZL200720170903.X) completely invalid due to a lack of inventiveness. This patent involves critical flow sensor components used in various products, such as anesthesia machines and ventilators. The dispute between the two medical makers dates back to April 2014 when Mindray sued Comen for patent infringement in the Shenzhen Intermediate People’s Court, requesting to freeze Comen’s bank accounts by using its factory as collateral. However, Comen did not back down. Instead, it launched a counteroffensive by requesting the CNIPA to invalidate Mindray's patent. In February 2015, the CNIPA partially invalidated the patent. Based on this decision, the Shenzhen Intermediate People’s Court ruled in August 2015 that Comen had infringed on the disputed patent. Comen then appealed to the Guangdong High Court and filed for another invalidation of Mindray's patent with the CNIPA. This marathon legal battle ultimately has seen the patent undergo seven invalidation challenges at the CNIPA, with four decisions issued. It has also been declared entirely invalid twice. The latest decision by the CNIPA secures a temporary victory for Comen, although Mindray may still appeal. Mindray has a history of litigating against Comen, achieving several victories. In September 2023, the Supreme People’s Court ordered Comen to cease manufacturing and selling seven products that infringed on Mindray’s "Portable Vital Signs Monitor" patent, awarding Mindray 5 million RMB in damages. Mindray has also sued other competitors to maintain its industry position. Despite its dominance in monitoring equipment, ventilators, anesthesia machines, and defibrillators, Mindray is facing aggressive advances from newcomers like Comen, leading to a shrinking market share. In 2023, Mindray led the domestic defibrillator market with a 48.77% share, while Comen and Anbao held 15.03% and 7.28%, respectively. By the first half of 2024, Mindray's share had fallen to 40.86%, with Comen and Anbao reaching 26.66% and 10.32%, respectively. Defibrillators are just one example. In the ventilator market, Mindray led the first half of the year with a 35.19% share, but Comen had already reached 14.86%. This fierce competition will inevitably continue to spill over into patent disputes. Photo: law.asia For more: https://lnkd.in/g86XM9Kj
To view or add a comment, sign in
-
China IP Weekly——the latest updates of global IP news #ChinaIP Focus 1. US, UK, EU sign first international #AI treaty 美国、英国和欧盟签署首个国际人工智能条约 2. #JPO releases 2025 IP Budget 日本专利局公布2025年知识产权预算 3. #Philips and #Thales settle global SEP disputes 飞利浦与泰雷兹就全球标准必要专利纠纷达成和解 IP Practice 4. #Cisco hit with $65.7 million verdict for infringing audio-conferencing patent 思科侵犯音频会议专利, 被判赔偿6570万美元 5. #ITC says Voltage did infringe on Shoals solar PV connector patents ITC裁定Voltage侵犯了Shoals的光伏连接器专利 6. Internet Archive loses appeal in copyright battle against publishers 互联网档案馆在与出版商的版权纠纷中败诉 7. #Nvidia, #Microsoft hit with patent lawsuit over AI computing technology 英伟达和微软被诉侵犯人工智能计算技术专利 8. UK competition regulator clears Microsoft's partnership with Inflection AI 英国竞争监管机构批准微软与Inflection AI的合作 Click to read the full article: https://lnkd.in/gx6DEK4Z
To view or add a comment, sign in
-
DT Mobile and Samsung settle RMB 123 million patent dispute DT Mobile and Samsung have resolved their patent disputes involving claims totaling RMB 123 million, according to an announcement made on August 29 by CICT Mobile, DT Mobile’s parent company. The settlement covers six patent infringement cases filed by DT Mobile against Samsung in the Fuzhou Intermediate People's Court. These disputes date back to early 2023, when DT Mobile accused Samsung China of infringing on six of its invention patents, seeking RMB 123 million in damages. Each case involved claims of RMB 20 million in economic damages and an additional RMB 500,000 in expenses related to stopping the infringement. A later report by the People’s Court Daily revealed that DT Mobile’s claims also included requests for the court to set global and domestic licensing terms for its 4G and 5G standard-essential patents, with a focus on licensing fee rates. Conflict between the two sides extended beyond China. In February 2023, DT Mobile also filed related lawsuits in Germany. In response, Samsung countered by suing DT Mobile in the U.S. District Court for the Eastern District of Virginia in October 2023, seeking a declaration of patent invalidity, alleging breach of contract, and claiming violation of the duty to negotiate in good faith. In April 2024, the Munich Regional Court ruled that Samsung’s 4G-enabled devices had infringed on DT Mobile’s standard-essential patent EP2237607. The court identified Samsung as an “unwilling” licensee and issued an injunction against Samsung’s products. Two months later, the companies submitted a joint stipulation of dismissal to the U.S. District Court for the Eastern District of Virginia, agreeing to end all ongoing litigation. Recently, the Fuzhou Intermediate People’s Court issued a civil ruling approving DT Mobile’s request to withdraw its six patent lawsuits. For more: https://lnkd.in/gTiwYTNs
To view or add a comment, sign in
-
#Fulbright's IPO thwarted by major patent disputes with #Johnson & Johnson Chinese medical device maker Fulbright Medical Inc.’s plans to list on the Shanghai Stock Exchange (SSE) have been thwarted due to extensive patent litigation. The company's IPO application, which was accepted on June 30, 2023, has now been officially terminated, as announced by the SSE on August 23. Fulbright’s IPO process was significantly hindered by ongoing patent disputes with Johnson & Johnson. These legal challenges were revealed in the company's first-round inquiry response, completed in January 2024. The legal troubles began in September 2019, when Johnson & Johnson subsidiaries Ethicon and Johnson & Johnson Shanghai filed four patent infringement lawsuits with the Shanghai Intellectual Property Court. These cases targeted Fulbright’s disposable endoscopic staplers and reload cartridges, with claims totaling nearly RMB 100 million. Notably, Johnson & Johnson accused Fulbright of infringing on patents ZL200680035337.X and ZL200810131706.6, seeking RMB 35.21 million in each case. For ZL200680035337.X, the court ruled against Fulbright, awarding RMB 5.6 million in damages, a decision upheld by the Supreme People’s Court. In the case involving ZL200810131706.6, however, an initial ruling of infringement was overturned on appeal after the patent was invalidated. Fulbright also faced mixed outcomes in other related cases. In one instance, the company successfully defended itself, which led Johnson & Johnson to withdraw its appeal. Another case, concerning a claim of RMB 28.16 million related to patent ZL200610126469.5, is currently under appeal after a favorable first-instance ruling for Fulbright. As Fulbright pursued its IPO, new legal challenges emerged. In August 2023, Cilag GmbH International and Johnson & Johnson Shanghai filed three additional patent infringement lawsuits with the Nanjing Intermediate People’s Court. These lawsuits accused Fulbright’s DSML and DSMM series products of infringing three separate patents, initially demanding RMB 5 million in damages per case. By March 2024, the claim in one case was increased to RMB 16.62 million, and further raised to RMB 53.9 million by June 2024, adding to Fulbright’s legal and financial burdens. Beyond China, Johnson & Johnson has also targeted Fulbright internationally. In 2018, Johnson & Johnson sued Fulbright in the Netherlands for copyright infringement and product imitation. The Rotterdam Court ruled against Fulbright, and this decision was upheld by the Hague Court of Appeal in 2022. Fulbright settled with Johnson & Johnson Netherlands by paying compensation in June 2023. Additionally, Johnson & Johnson has filed a lawsuit against Fulbright’s Brazilian client, Scitech, for patent infringement. Although Fulbright is not directly involved in this case, its manufacturing role continues to attract scrutiny. For more: https://lnkd.in/dBWaQpXm Photo: Fulbright
To view or add a comment, sign in
873 followers